Top

Published in:

01-01-2013 | Research Article

Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel^TM

Authors: Alka Madaan, Pratibha Singh, Anshumali Awasthi, Ritu Verma, Anu T. Singh, Manu Jaggi, Shiva Kant Mishra, Sadanand Kulkarni, Hrishikesh Kulkarni

Published in: Clinical and Translational Oncology | Issue 1/2013

Abstract

Introduction

An increasing research interest has been directed toward nanoparticle-based drug delivery systems for their advantages. The appropriate amalgamation of pH sensitivity and tumor targeting is a promising strategy to fabricate drug delivery systems with high efficiency, high selectivity and low toxicity.

Materials and Methods

A novel pH sensitive Cremophor-free paclitaxel formulation, Nanoxel^TM, was developed in which the drug is delivered as nanomicelles using a polymeric carrier that specifically targets tumors. The efficiency and mechanism of intracellular paclitaxel delivery by Nanoxel^TM was compared with two other commercially available paclitaxel formulations: Abraxane^TM and Intaxel^TM, using different cell lines representing target cancers [breast, ovary and non-small cell lung carcinoma (NSCLC)] by transmission electron microscopy and quantitative intracellular paclitaxel measurements by high performance liquid chromatography.

Results

The data obtained from the present study revealed that the uptake of nanoparticle-based formulations Nanoxel^TM and Abraxane^TM is mediated by the process of endocytosis and the uptake of paclitaxel was remarkably superior to Intaxel^TM in all cell lines tested. Moreover, the intracellular uptake of paclitaxel in Nanoxel^TM- and Abraxane^TM-treated groups was comparable. Hence, the nanoparticle-based formulations of paclitaxel (Nanoxel^TM and Abraxane^TM) are endowed with higher efficiency to deliver the drug to target cells as compared to the conventional Cremophor-based formulation.

Conclusion

Nanoxel^TM appears to be of great promise in tumor targeting and may provide an advantage for paclitaxel delivery into cancer cells.

Mo Y, Lim LY (2005) Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release 108(2–3):244–262PubMedCrossRef

Ebbesen M, Jensen TG (2006) Nanomedicine: techniques, potentials, and ethical implications. J Biomed Biotechnol 2006(5):51516PubMed

Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL (2001) The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598PubMedCrossRef

Kloover JS, Den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90(2):304–305PubMedCrossRef

Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609–621PubMedCrossRef

Skwarczynski M, Hayashi Y, Kiso Y (2006) Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem 49(25):7253–7269PubMedCrossRef

Brahmachari BH, Hazra A, Majumdar A (2011) Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: an observational study. Indian J Pharmacol. 43(2):126–130PubMedCrossRef

Charoentum C, Thongprasert S, Chewasakulyong B (2007) Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer. Gan To Kagaku Ryoho 34(10):1603–1607PubMed

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res 12(4):1317–1324CrossRef

10.

Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A et al (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11(11):4136–4143PubMedCrossRef

11.

Fader AN, Rose PG (2009) Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 19(7):1281–1283PubMedCrossRef

12.

Feng T, Szabo E, Dziak E, Opas M (2010) Cytoskeletal disassembly and cell rounding promotes adipogenesis from ES cells. Stem Cell Rev 6(1):74–85

13.

Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle–albumin-bound paclitaxel. Expert Opin Pharmacother 11(8):1413–1432

14.

Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, et al (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52(1):140–146

15.

Huh JW, Kim HR (2009) Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0? J Surg Oncol 100(5):387–391PubMedCrossRef

16.

van Vlerken LE, Amiji MM (2006) Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 3(2):205–216PubMedCrossRef

17.

Wang SH, Lee CW, Chiou A, Wei PK (2010) Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images. J Nanobiotechnology 8:33

18.

Jin C, Bai L, Wu H, Tian F, Guo G (2007) Radiosensitization of paclitaxel, etanidazole and paclitaxel + etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials 28(25):3724–3730PubMedCrossRef

19.

Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598PubMedCrossRef

20.

Liaudet L, Soriano FG, Szabo C (2000) Biology of nitric oxide signaling. Crit Care Med 28(4 Suppl):N37–N52PubMedCrossRef

21.

Jang SH, Wientjes MG, Lu D, Au JL (2003) Drug delivery and transport to solid tumors. Pharm Res 20(9):1337–1350PubMedCrossRef

22.

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249PubMedCrossRef

23.

Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res Official J Am Assoc Cancer Res 14(5):1310–1316CrossRef

24.

Singh AT, Jaggi M, Khattar D, Awasthi A, Mishra SK, Tyagi S et al (2008) A novel nanopolymer based tumor targeted delivery system for paclitaxel. J Clin Oncol 26(May 20 suppl; abstr 11095)

Title: Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
Authors: Alka Madaan
Pratibha Singh
Anshumali Awasthi
Ritu Verma
Anu T. Singh
Manu Jaggi
Shiva Kant Mishra
Sadanand Kulkarni
Hrishikesh Kulkarni
Publication date: 01-01-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0883-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010

Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome

A 10-year step forward in hereditary cancer in Spain

Intra-operative electron beam radiotherapy for newly diagnosed and recurrent malignant gliomas: feasibility and long-term outcomes

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience

Tumor bed segmentation: first step for partial breast irradiation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer